We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Advertisement

Long-term PD-1/PD-L1 inhibitor therapy leads to late irAEs

    • 21 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Hall KH, et al. New and Worsening Long-term, Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer. Pharmacotherapy : 12 Dec 2019. Available from: URL: http://doi.org/10.1002/phar.2354

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Long-term PD-1/PD-L1 inhibitor therapy leads to late irAEs. Reactions Weekly 1786, 9 (2020). https://doi.org/10.1007/s40278-020-73483-0

    Download citation